Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PSN-357
- Development stage
- Phase 2
- Lead developer
- Prosidion
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
**PSN-357** is a small molecule glycogen phosphorylase inhibitor developed by Prosidion (a subsidiary of OSI Pharmaceuticals) for type 2 diabetes and obesity. It prevents glycogen breakdown to glucose in the liver, rapidly lowering blood glucose levels, but its clinical development was discontinued due to poor selectivity between liver and muscle isoforms, leading to side effects like muscle fatigue. A Phase II trial evaluated its safety, tolerability, and exercise tolerance in diabetics.[1][5][7]
- Other names
- SCHEMBL2607197SCHEMBL-2607197SCHEMBL 2607197
02
Targets
PYGB (Glycogen phosphorylase, brain form)PYGL (Glycogen phosphorylase, liver form)PYGM (Glycogen phosphorylase, muscle form)
Beyond the preview
Go deeper on PSN-357.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PSN-357.